# Krystal Biotech, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Krystal Biotech, Inc.). ## Overview Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines built on an engineered HSV-1 gene therapy platform. Its first approved product, VYJUVEK, treats dystrophic epidermolysis bullosa and is being commercialized in the U.S., Europe, and Japan, while the company also advances a pipeline of rare-disease and aesthetic skin programs. ## Products & services • VYJUVEK (beremagene geperpavec-svdt / B-VEC) for DEB • HSV-1-based gene therapy vectors and transgene delivery platform • Commercial manufacturing of genetic medicines in-house • Clinical-stage pipeline for rare and serious diseases • Preclinical aesthetic skin programs through Jeune Aesthetics - **Commercial product: VYJUVEK** (95%) — Approved topical gene therapy for dystrophic epidermolysis bullosa sold in the U.S., EU, and Japan. - **Pipeline genetic medicines** (3%) — Clinical-stage product candidates targeting rare and serious diseases beyond DEB. - **Aesthetic skin programs** (1%) — Preclinical programs under Jeune Aesthetics focused on aesthetic dermatology applications. - **Platform and manufacturing capabilities** (1%) — Proprietary HSV-1 vector technology, purification processes, assays, and CGMP manufacturing. - VYJUVEK for dystrophic epidermolysis bullosa (DEB) - B-VEC outside the U.S., Europe, and Japan - HSV-1-based gene therapy vector platform - Commercial-scale CGMP manufacturing facilities - Clinical-stage rare disease pipeline - Preclinical aesthetic skin condition programs ## Customers Krystal Biotech sells primarily to patients with dystrophic epidermolysis bullosa through healthcare providers, specialty pharmacies, and distributors, because VYJUVEK is administered in clinical or home-care settings. Outside the U.S. and major European markets, the company relies on specialty distributors to reach patients and support market access. Its pipeline and preclinical programs are not yet commercial products, so current customer demand is concentrated in the rare-disease treatment channel. - **DEB patients and caregivers** (primary) — Buy VYJUVEK through the care pathway because it is the only approved corrective therapy for DEB and can be used in office or home settings. - **Specialty clinicians and treatment centers** (primary) — Prescribe and administer VYJUVEK for patients with severe dystrophic epidermolysis bullosa and manage ongoing treatment. - **Specialty pharmacies and reimbursement intermediaries** (primary) — Support dispensing, reimbursement approvals, and patient access, which directly affects commercial uptake. - **Regional specialty distributors** (secondary) — Buy and distribute VYJUVEK in markets outside the U.S., major EU countries, the UK, and Japan. - **Research and development partners / future patients** (emerging) — Not current revenue customers, but important for future pipeline commercialization and expansion into new indications. - DEB patients needing a corrective therapy for skin wounds - Dermatologists and specialty clinicians prescribing VYJUVEK - Specialty pharmacies handling reimbursement and distribution - Regional specialty distributors outside core direct markets - Healthcare systems and payors evaluating access and coverage ## Geography The company is headquartered in Pittsburgh, Pennsylvania and operates as a global commercial-stage biotech with in-house manufacturing in the U.S. It launched VYJUVEK in the U.S. in 2023, began launches in Europe and Japan in 2025, and is expanding through specialty distributors in Central and Eastern Europe, the Middle East, and Turkey. Geography matters because commercialization, reimbursement, and regulatory approval are managed market by market, creating different launch timing and execution risk across regions. - **United States** (70%) — Core commercial market and first launch geography for VYJUVEK. - **Europe** (20%) — Includes direct and distributor-led commercialization across major EU markets and the UK. - **Japan** (5%) — Launched in October 2025 after pricing negotiations. - **Rest of world** (5%) — Distributor-covered territories including Central/Eastern Europe and the Middle East. - Headquartered in Pittsburgh, Pennsylvania, United States - U.S. launch began in 2023 and remains the core market - Europe and Japan launches started in 2025 - Specialty distributors cover Central/Eastern Europe, Middle East, Turkey - Wholly owned subsidiaries support commercialization in Europe and Japan ## Strategy Krystal Biotech’s strategy is to maximize VYJUVEK adoption in DEB while expanding geographically through direct commercialization in core markets and distributors elsewhere. At the same time, it is using its HSV-1 platform and internal manufacturing base to build a broader pipeline that can reduce dependence on a single product over time. The company also continues to invest in regulatory approvals, market access, and manufacturing scale to support global launches. - **Globalize VYJUVEK commercialization** (short-term) — VYJUVEK is the company’s main revenue driver, so broader launch execution is central to growth. - **Build a broader pipeline from the HSV-1 platform** (medium-term) — A second or third product would reduce concentration risk and extend the platform’s value. - **Maintain manufacturing and quality control in-house** (medium-term) — Internal CGMP capacity supports supply reliability, product quality, and margin control. - Expand VYJUVEK adoption in the U.S., Europe, and Japan - Use specialty distributors to reach smaller international markets - Advance pipeline programs beyond DEB to diversify revenue - Leverage in-house CGMP manufacturing for supply control - Invest in market access, medical affairs, and reimbursement support ## Risks The company is highly dependent on VYJUVEK, so any slower-than-expected adoption, reimbursement friction, safety issue, or competitive product could materially affect results. International expansion adds regulatory, distributor, and execution risk, while biotech development risk remains high because pipeline programs may fail in clinical testing or never reach approval. As a commercial biotech, it also faces cybersecurity, manufacturing, and variable-consideration revenue recognition risks that can create quarter-to-quarter volatility. - **Dependence on VYJUVEK commercial success** [high] — Near-term revenue and future growth are substantially tied to one approved product. - **International regulatory and market access execution** [high] — Approval, pricing, and reimbursement differ by country and can delay or limit uptake. - **Competitive pressure in gene therapy and DEB** [medium] — Competitors may launch safer, cheaper, or more convenient therapies first. - **Cybersecurity and third-party service disruption** [medium] — A 2024 incident at a specialty pharmacy provider delayed reimbursement approvals and hurt revenue. - **Clinical development failure** [medium] — Pipeline candidates may not demonstrate efficacy or obtain approval, limiting diversification. - Heavy dependence on VYJUVEK creates single-product concentration risk - Regulatory and reimbursement delays can slow launches outside core markets - Competition from alternative gene therapies and palliative treatments is intense - Manufacturing or quality issues could disrupt supply and commercialization - Cybersecurity incidents can delay reimbursement and hurt product revenue ## Accounting Revenue is recognized under ASC 606 and includes estimates of variable consideration such as discounts, returns, copay assistance, and rebates, which can materially affect reported product revenue. Because VYJUVEK sales are still ramping and launches are staggered by geography, quarterly revenue can be volatile and sensitive to reimbursement timing and distributor inventory movements. Investors should also watch stock-based compensation, accrued expenses, valuation allowances, and capitalized facility spending tied to ASTRA and other CGMP assets. - **Revenue recognition and variable consideration** — Can change reported sales and margins quarter to quarter - **Quarterly launch timing and seasonality** — Creates comparability issues across quarters and regions - **Stock-based compensation** — Affects reported operating loss and non-cash expense trends - **Capitalized manufacturing facilities and depreciation** — Influences gross margin, operating expense, and cash flow - **Valuation allowance on deferred tax assets** — Can materially affect tax expense and equity - Variable consideration affects net product revenue for VYJUVEK - Quarterly revenue can swing with launch timing and reimbursement approvals - Stock-based compensation is a meaningful operating expense estimate - Accrued expenses and valuation allowances rely on management judgment - Capital expenditures for ASTRA affect depreciation and cash flow --- *Last updated: 2026-04-28T20:20:41.934105+00:00*